The high rate of PD-L1 expression in NSCLC driven by EGFR and ALK alterations was accompanied by a prevalence of low immunogenicity with the prevalence of ID TME in EGFR mutant tumors and IE TME in ALK-rearranged and KRAS mutant tumors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.